Velorum Therapeutics Analysis
What is Velorum Therapeutics?
Velorum Therapeutics develops medicines around heme biology, with a stated emphasis on porphyrin-scavenging and heme-sequestering technologies. Its pipeline centers on rare erythropoietic porphyrias and heme injury conditions, including kidney, heart, liver, and oncology applications. The company says it was founded by twin brothers Parsa and Pouya Modareszadeh and launched with Y Combinator backing.
Location
329 Oyster Point Blvd, South San Francisco, California 94080, United States
Employees
1-10
Founded
2023
Revenue
<$5M
Product Features & Capabilities
- cancer therapies targeting metabolic vulnerabilities, innovative treatments for porphyrias, drugs that disrupt tumor metabolism, therapies that unlock the biology of heme
Who are the founders of Velorum Therapeutics
PM
Pouya Modareszadeh
Co-Founder & CEO
PM
Parsa Modareszadeh
Co-Founder and President
HQ Full Address
329 Oyster Point Blvd, South San Francisco, California 94080, United States
Market Focus
Velorum Therapeutics primarily focuses on the biotechnology industry, specifically developing innovative therapies targeting the biology of heme to address unmet medical needs in diseases such as porphyrias and cancer.
Investors
- Y Combinator
- Ritual Capital
- Metaplanet Holdings
- Transpose Platform Management
Business Model
Bootstrapped revenue model focusing on innovative therapies and strategic funding rounds.
Competitors Overview
Velorum Therapeutics operates in a niche market focused on developing therapies that target heme biology, particularly for conditions like porphyrias and cancer. Its main competitors include:
-
Disc Medicine: This company is developing therapies for hematologic diseases, including erythropoietic protoporphyria. Their pipeline includes bitopertin, which targets the same patient population as Velorum's therapies. Disc Medicine's advantage lies in its focus on a broader range of hematologic conditions, potentially allowing for a more extensive market reach.
-
Givosiran: This is an RNA interference therapy specifically designed for acute intermittent porphyria. It works by inhibiting the hepatic ALAS1 enzyme, which is crucial in heme production. Givosiran's advantage is its targeted mechanism of action, which directly addresses the underlying cause of the disease, offering a potentially more effective treatment option for patients.
These competitors highlight the competitive landscape in the heme-targeted therapy market, with each company bringing unique approaches and advantages to their respective treatments.
See something that needs updating? Suggest edits to this profile.